Display options
Cite
Ranjan A, Iyer SV, Ward C, et al. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018;9(30):21429-21443doi: 10.18632/oncotarget.25117.
Ranjan, A., Iyer, S. V., Ward, C., Link, T., Diaz, F. J., Dhar, A., Tawfik, O. W., Weinman, S. A., Azuma, Y., Izumi, T., & Iwakuma, T. (2018). MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget, 9(30), 21429-21443. https://doi.org/10.18632/oncotarget.25117
Ranjan, Atul, et al. "MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma." Oncotarget vol. 9,30 (2018): 21429-21443. doi: https://doi.org/10.18632/oncotarget.25117
Ranjan A, Iyer SV, Ward C, Link T, Diaz FJ, Dhar A, Tawfik OW, Weinman SA, Azuma Y, Izumi T, Iwakuma T. MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20. PMID: 29765550; PMCID: PMC5940416.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Apr 20;9(30):21429-21443. doi: 10.18632/oncotarget.25117. eCollection 2018 Apr 20.

MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma.

Oncotarget

Atul Ranjan, Swathi V Iyer, Christopher Ward, Tim Link, Francisco J Diaz, Animesh Dhar, Ossama W Tawfik, Steven A Weinman, Yoshiaki Azuma, Tadahide Izumi, Tomoo Iwakuma

Affiliations

  1. Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, USA.
  2. Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
  3. Department of Pathology, University of Kansas Medical Center, Kansas City, KS, USA.
  4. Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
  5. Department of Molecular Bioscience, University of Kansas, Lawrence, KS, USA.
  6. Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Lexington, KY, USA.
  7. Children's Research Institute, Children's Mercy Hospital and Clinics, Kansas City, MO, USA.

PMID: 29765550 PMCID: PMC5940416 DOI: 10.18632/oncotarget.25117

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and the prognosis of HCC patients, especially those with metastasis, remains extremely poor. This is partly due to unclear molecular mechanisms underlying HCC metastasis. Our previous study indicates that MDM2 Binding Protein (MTBP) suppresses migration and metastasis of HCC cells. However, signaling pathways regulated by MTBP remain unknown. To identify metastasis-associated signaling pathways governed by MTBP, we have performed unbiased luciferase reporter-based signal array analyses and found that MTBP suppresses the activity of the ETS-domain transcription factor Elk-1, a downstream target of Erk1/2 MAP kinases. MTBP also inhibits phosphorylation of Elk-1 and decreases mRNA expression of Elk-1 target genes. Reduced Elk-1 activity is caused by inhibited nuclear translocation of phosphorylated Erk1/2 (p-Erk) by MTBP and subsequent inhibition of Elk-1 phosphorylation. We also reveal that MTBP inhibits the interaction of p-Erk with importin-7/RanBP7 (IPO7), an importin family member which shuttles p-Erk into the nucleus, by binding to IPO7. Moreover, high levels of MTBP in human HCC tissues are correlated with cytoplasmic localization of p-Erk1/2. Our study suggests that MTBP suppresses metastasis, at least partially, by down-modulating the Erk1/2-Elk-1 signaling pathway, thus identifying a novel regulatory mechanism of HCC metastasis by regulating the subcellular localization of p-Erk.

Keywords: Elk-1; Erk1/2; MDM2; MTBP; metastasis

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

References

  1. Science. 2013 May 24;340(6135):981-4 - PubMed
  2. Am Surg. 2003 Oct;69(10):879-85 - PubMed
  3. J Biol Chem. 2000 Oct 13;275(41):31883-90 - PubMed
  4. Oncotarget. 2016 Jul 19;7(29):45302-45316 - PubMed
  5. Genes Cancer. 2011 Mar;2(3):195-209 - PubMed
  6. Hepatology. 2000 Nov;32(5):958-61 - PubMed
  7. Mol Cancer Res. 2014 Sep;12(9):1216-24 - PubMed
  8. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7170-5 - PubMed
  9. Biochem Biophys Res Commun. 2006 Jan 6;339(1):217-25 - PubMed
  10. Cancer Res. 2014 Jul 1;74(13):3591-602 - PubMed
  11. Zhonghua Zhong Liu Za Zhi. 2009 May;31(5):340-5 - PubMed
  12. J Hepatol. 2008 Jan;48(1):83-90 - PubMed
  13. Oncogene. 2010 Jun 3;29(22):3287-96 - PubMed
  14. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  15. EMBO J. 2007 Feb 7;26(3):635-46 - PubMed
  16. Oncogene. 2002 Sep 19;21(42):6434-45 - PubMed
  17. Biochem Biophys Res Commun. 2007 May 4;356(2):341-7 - PubMed
  18. Mol Cell. 2008 Sep 26;31(6):850-61 - PubMed
  19. Am J Physiol. 1997 Apr;272(4 Pt 1):G721-6 - PubMed
  20. Anticancer Res. 2015 Apr;35(4):1967-76 - PubMed
  21. Cancer. 2011 Jul 1;117(13):2939-50 - PubMed
  22. Development. 2001 Apr;128(8):1403-14 - PubMed
  23. J Mol Cell Biol. 2012 Jun;4(3):153-63 - PubMed
  24. Cancer Res. 2010 Jul 15;70(14):5649-69 - PubMed
  25. Oncogene. 2013 Jan 24;32(4):462-70 - PubMed
  26. Biochim Biophys Acta. 2013 Oct;1829(10):1026-33 - PubMed
  27. Oncotarget. 2016 Mar 8;7(10 ):11595-608 - PubMed
  28. Clin Exp Metastasis. 2015 Apr;32(4):301-11 - PubMed
  29. Oncotarget. 2017 Feb 14;8(7):12174-12185 - PubMed
  30. PLoS Genet. 2012;8(5):e1002694 - PubMed
  31. PLoS One. 2015 May 26;10(5):e0127420 - PubMed
  32. F1000Prime Rep. 2013 Oct 01;5:41 - PubMed
  33. Cell Biol Int. 2008 Feb;32(2):210-6 - PubMed
  34. Cell Biochem Funct. 2013 Jun;31(4):319-24 - PubMed
  35. Nature. 1991 Dec 19-26;354(6354):531-4 - PubMed
  36. Cancer Metastasis Rev. 2015 Dec;34(4):635-41 - PubMed
  37. Cancer Metastasis Rev. 2012 Dec;31(3-4):633-40 - PubMed
  38. Cell Death Differ. 2011 Jul;18(7):1208-19 - PubMed
  39. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  40. Mol Cell Biol. 2005 Jan;25(2):545-53 - PubMed
  41. Acta Pharmacol Sin. 2012 May;33(5):691-700 - PubMed

Publication Types

Grant support